Industry News

News Powered By:

- a collaborative partner.


 


Medimmune, Cancer Research U.K. establish laboratory for biologic cancer medicines


CenterWatch News Online Headlines : September 26, 2014 10:24 am : Centerwatch

MedImmune, AstraZeneca’s global biologics R&D arm, and Cancer Research U.K., with its commercial arm Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, U.K. The new laboratory will focus on the discovery and development of novel biologic cancer treatments over an initial five-year period.



Radiant/CRA enrolls 8,000 in hepatitis B vaccine study


CenterWatch News Online Headlines : September 26, 2014 10:23 am : Centerwatch

Radiant Research/Clinical Research Advantage (CRA), a Tempe, Ariz., wholly owned clinical trial site management organization, has completed enrollment for the Dynavax Technologies phase III clinical trial of HEPLISAV-B, an investigational adult hepatitis B vaccine.



Cancer Core Europe consortium launches to address the cancer care


CenterWatch News Online Headlines : September 26, 2014 10:15 am : Centerwatch

Cancer Core Europe—a consortium to address the cancer care/research continuum challenge, has launched. Its members are Gustave Roussy Cancer Campus Grand Paris; Cambridge Cancer Center, based in the U.K.; Karolinska Institute, of Stockholm, Sweden; the Netherlands Cancer Institute; Vall d’Hebron Institute of Oncology (VHIO), of Barcelona, Spain; and the German Cancer Research Center (DKFZ) and its National Center for Tumor Diseases (NCT).



Soligenix awarded $24.7M NIAID contract for heat stable RiVax vaccine


CenterWatch News Online Headlines : September 26, 2014 10:05 am : Centerwatch

Soligenix, a Princeton, N.J.-based late-stage biopharmaceutical company developing products that address unmet medical needs in inflammation, oncology and biodefense, has been awarded a contract valued at up to $24.7 million inclusive of options by the U.S. Department of Health and Human Service’s NIH, specifically funded by the National Institute of Allergy and Infectious Diseases (NIAID). The objectives of the contract are to advance the development of Soligenix’s thermostabilization technology, ThermoVax, combined with the company’s ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.



Thermo Fisher Scientific inks agreement with GlaxoSmithKline, Pfizer


CenterWatch News Online Headlines : September 26, 2014 10:01 am : Centerwatch

Thermo Fisher Scientific, a Waltham, Mass.-based healthcare equipment company, has inked an agreement with GlaxoSmithKline and Pfizer to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs.


« Page 1, 2, 3418, »